Company / Gross Margin
Jazz Pharmaceuticals Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
29.0%
FY2019
5-year range
-
FY2016-FY2019
Trend
+6.1%
vs FY2018
Sector context
#27 of 28
Health Care
What the data says
Among 28 Health Care companies, Jazz Pharmaceuticals is in the bottom 4% for gross margin. Declined from 92.7% to 29.0% over the past 2 years.
Based on SEC 10-K filings.
29.0% in FY2019 with a 3-year CAGR of +2.6%.
Declined from 92.7% to 29.0% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- +2.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 28This company 29.0% Sector average 60.3%
▼
-51.9% below sector average
Key checks
Key Insights
- In FY2019, gross margin increased 6.1% year-over-year.
- Currently 31.3pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 29.0% | +6.1% |
| FY2018 | 27.4% | -70.5% |
| FY2017 | 92.7% | +250.2% |
| FY2016 | 26.5% | +25.8% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026